No Matches Found


Loading...
{{stock_short.stock.stock_name.value}}
{{stock_short.stock.price.value}}
{{stock_short.stock.price_difference.value}} ({{stock_short.stock.price_percentage.value}}%)
{{ra.field}}
{{ra.stock_return.chgp}}%
{{ra.sensex_return.chgp}}%
{{stock_short.result_details[0].header}}
{{stock_short.result_details[0].latest.to_period}}
{{stock_short.result_details[0].latest.from_period}}
Change%
{{latest.field}}
{{latest.to}}{{latest.value_suffix}}
{{latest.from}}{{latest.value_suffix}}
{{latest.per}}
Figures in Rs cr

NexgenRx Adjusts Financial Evaluation, Highlighting Key Metrics and Market Position

NexgenRx, Inc. has recently experienced an evaluation adjustment, indicating significant changes in its financial metrics. Key indicators include a P/E ratio of 20, a price-to-book value of 2.66, and a PEG ratio of 0.07, reflecting its competitive positioning and operational efficiency within the market.

Sep 03 2025 04:43 PM IST
share
Share Via
NexgenRx Adjusts Financial Evaluation, Highlighting Key Metrics and Market Position

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via
{{list.post_title_sep}}

{{list.post_title}}

{{list.post_excerpt}}

{{list.post_date_sep}}
share
Share Via

Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read